A bacterial enzyme called histidine kinase is a promising target for new classes of antibiotics. However, it has been difficult to develop drugs that target this enzyme, because it is a "hydrophobic" protein that loses its structure once removed from its normal location in the cell membrane.

Now, an MIT-led team has found a way to make the enzyme water-soluble, which could make it possible to rapidly screen potential drugs that might interfere with its functions.

Researchers from Nagoya University Graduate School of Medicine in Japan have successfully treated the skin diseases epidermolytic ichthyosis (EI) and ichthyosis with confetti (IWC) by transplanting genetically healthy skin to inflamed areas. Transplanting healthy skin to inflamed areas has been used as a treatment option for severe burn injuries. They applied this technique from a common disease to rare diseases.

Diabetes rates continue to rise, with 11.7 million Canadians living with diabetes or pre-diabetes. At UBC, scientists have created a pain-free drug delivery method to help people with diabetes manage the disease and maintain their health more easily.

Researchers at the Li Lab have developed oral insulin drops that when placed under the tongue are quickly and efficiently absorbed by the body, potentially replacing the need for insulin injections.

GSK plc (LSE/NYSE: GSK) today announced that it has acquired Elsie Biotechnologies, a San Diego-based private biotechnology company dedicated to unlocking the full potential of oligonucleotide therapeutics, for up to $50 million (approximately £39 million).

Oligonucleotides have a unique ability to modulate gene expression, making them an attractive modality to address a significant proportion of therapeutic targets that are not amenable to traditional small molecules or biologics.

Moderna’s mRNA Candidate Joins FDA’s Accelerator Program for Rare Diseases 6/6/2024

Novo’s Ozempic, Wegovy to Face Stiff Generic Competition in China: Reuters 6/6/2024

Amgen Phase III Win Positions Uplizna for Label Expansion in Rare Autoimmune Disease 6/6/2024

BioSpace x DIA: Robust Integrated Regulatory Strategies 6/6/2024

Life Sciences R&D, Manufacturing Talent Becoming More Difficult to Find: Report 6/6/2024

Embracing Inclusivity: How Biopharmas Connect With LGBTQ+ Employees 6/6/2024

Telix Targets $200M IPO in Hot Radiopharma Market as Biotech Nasdaq Offerings Slow 6/6/2024

You’re More Than Your Job: Finding Self-Worth Outside of Work 6/6/2024

Blocking a protein known as CDK7 could prevent heart damage associated with a commonly used cancer chemotherapy medication, according to a study led by scientists at Washington State University. Importantly, the researchers also found that inhibiting CDK7 could help enhance the medication's cancer-killing capability.

Based on an animal model, the study findings could provide a foundation for future treatment strategies to reduce chemotherapy-related heart toxicity and increase treatment effectiveness.

ASGCT 2024 Comes at Pivotal Time for Gene and Cell Therapy Sector 5/6/2024

Opinion: Can Ketamine Be Safely Used at Home? 5/6/2024

5 DMD Data Readouts to Watch in 2024 5/6/2024

AAVs in Focus at ASGCT: Improved Precision, Targeting Common Diseases 5/6/2024

In an era marked by rapid technological advancement in biomedical engineering, a groundbreaking development is set to revolutionize our approach to drug testing and disease modeling. Researchers from Shanghai University and the University of California Los Angeles have made significant strides in the field of in vitro vascularized organ-on-a-chip systems, offering a promising alternative to traditional methods that rely heavily on animal testing and simplistic two-dimensional cell cultures.

FDA Greenlights BMS, J&J CAR-T Therapies for Earlier Multiple Myeloma Treatment 4/6/2024

A novel immunotherapy approach developed by Ludwig Cancer Research scientists employs a two-pronged attack against solid tumors to boost the immune system’s ability to target and eliminate cancer cells.​​​​​​

The research focuses on an immunotherapy called adoptive cell transfer (ACT), which involves extracting T cells from a patient, enhancing their ability to fight cancer, expanding them in culture and reinfusing them into the patient's body.